Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-22-006707
Filing Date
2022-04-29
Accepted
2022-04-29 16:01:52
Documents
4
Period of Report
2022-06-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A ovid_proxy_2022.htm DEF 14A 1125961
2 GRAPHIC img156521292_0.jpg GRAPHIC 11431
3 GRAPHIC img156521292_1.jpg GRAPHIC 214137
4 GRAPHIC img156521292_2.jpg GRAPHIC 103749
  Complete submission text file 0000950170-22-006707.txt   1580893
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38085 | Film No.: 22875054
SIC: 2834 Pharmaceutical Preparations